Comments
Strides Pharma Science on Wednesday said its step-down wholly-owned subsidiary has received approval from the US health regulator for Ethosuximide Softgel capsules, an anti-epileptic medication.
The approved product is a generic version of Zarontin Capsules, 250 mg, of Pfizer.
“Strides Pharma Global, Singapore, has received approval for Ethosuximide Softgel Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA),” Strides Pharma Science said in a BSE filing.
The product was approved in the first review cycle by the USFDA in less than 10 months of filing.
Citing IQVIA data, the company said the US market for Ethosuximide Softgel Capsules USP, 250 mg, is approximately $10 million.
Strides said Ethosuximide Softgel capsules are part of its niche and small volume product portfolio with limited competition in the US market.
“As part of its portfolio maximisation strategy, Strides will also commercialise the product in other geographies, leveraging its vast footprint in other regulated markets,” the company added.
The company’s stock was trading 0.46 per cent higher at Rs 404.75 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.